ImpactLab makes strategy consulting accessible to early-stage start-ups that expand access, equity, and inclusion. In doing so, we hope to empower innovations that improve medicine for all patients.
Disrupting precision medicine requires investing in innovation that expands access, equity, and inclusion.
DeciBio's strategy consulting business already drives disruption and innovation in precision medicine. DeciBio's ImpactLab takes our mission one step further.
We designed ImpactLab with 3 key goals in mind, each of which will help inform our chosen start-up partner from each application cycle:
We encourage other precision medicine start-ups to contact our consulting team to find out other ways we can work together!
Each year, ImpactLab enrolls at least one early-stage start-up in an 8-week program. During this program, DeciBio provides the start-up with strategic guidance relating to its market and competitive landscape, stakeholder / customer dynamics, and go-to-market / commercial strategy.
While ImpactLab is not 100% "pro bono" (i.e., completely free-of-charge), we significantly reduce our fees and expenses to make the cost of participating as nominal as possible. ImpactLab is designed this way to maximize thoughtful engagement with and implementation of key insights, not to recoup any costs or obtain equity for conducting this not-for-profit program.